Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Stock Information for Rigel Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Rigel Pharmaceuticals Inc.

Rigel to Present at the Jefferies Global Healthcare Conference
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress
Rigel Reports First Quarter 2025 Financial Results and Provides Business Update
Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation
Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors
Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.